Sustained release formulations of psychoactive drugs
View Patent ↗This invention provides biodegradable, sustained-release pharmaceutical compositions of a psychoactive drug formulated with biocompatible, biodegradable tyrosine-derived polyarylates.
1. A sustained-release formulation comprising a tyrosine-derived polyarylate having at least one p(DT-succinate) group and a psychoactive drug physically admixed, dissolved, dispersed, or embedded within said tyrosine-derived polyarylate, and wherein said tyrosine-derived polyarylate and said psychoactive drug form a homogeneous solid matrix, and wherein said formulation provides a burst-free, sustained release of said psychoactive drug.
2. The formulation according to claim 1 , wherein when measured in vitro under physiological conditions at 37° C., amounts are such that the formulation releases the psychoactive for at least 1 to 5 days.
3. The formulation of claims 2 , wherein the physiological conditions are in phosphate buffered saline (PBS).
4. The formulation according to claim 1 , wherein the psychoactive drug is an atypical psychoactive drug.
5. The formulation according to claim 4 , wherein the atypical psychoactive drug is olanzapine.
6. The formulation according to claim 1 , wherein the formulation is prepared as a microparticle or a microsphere.
7. The formulation according to claim 1 , wherein the tyrosine-derived polyarylate is a poly(DT-DTE succinate) or a poly(DTE succinate), wherein, DT, when present ranges from about 5% to about 50%, from about 5% to about 30%, from about 10% to about 20% of the polyarylate or is about 5%, 10%, 15%, 20%, 25% or 30% of said polyarylate.
8. The formulation according to claim 1 , wherein the formulation comprises an amount of psychoactive drug ranging from about 10% to about 40% by weight.
9. A sustained-release formulation comprising a tyrosine-derived polyarylate and a psychoactive drug physically admixed, dissolved, dispersed, or embedded within said tyrosine-derived polyarylate, and wherein said tyrosine-derived polyarylate and said psychoactive drug form a homogeneous solid matrix, and wherein said formulation is prepared as a solvent-cast film or a solvent-free film.
10. The formulation according to claim 9 , wherein when measured in vitro under physiological conditions at 37° C., amounts are such that the formulation releases the psychoactive for at least 1 to 5 days.
11. The formulation of claim 8 , wherein the physiological conditions are in phosphate buffered saline (PBS).
12. The formulation according to claim 9 , wherein the psychoactive drug is an atypical psychoactive drug.
13. The formulation according to claim 12 , wherein the atypical psychoactive drug is olanzapine.
14. The formulation according to claim 9 , wherein the psychoactive drug is olanzapine.
15. The formulation according to claim 9 , wherein the formulation is prepared as a microparticle or a microsphere.
16. The formulation according to claim 9 , wherein the formulation comprises an amount of psychoactive drug ranging from about 10% to about 40% by weight.
17. A burst-free, sustained-release microsphere or microparticle comprising a tyrosine-derived polyarylate having at least one p(DT-succinate) group and a psychoactive drug.
18. The microsphere or microparticle according to claim 17 , wherein when measured in vitro under physiological conditions at 37° C., amounts are such that the formulation releases the psychoactive for at least 1 to 5 days.
19. The microsphere or microparticle of claims 18 , wherein the physiological conditions are in phosphate buffered saline (PBS).
20. The microsphere or microparticle according to claim 17 , wherein the psychoactive drug is an atypical psychoactive drug.
21. The microsphere or microparticle according to claim 17 , wherein the atypical psychoactive drug is olanzapine.
22. The microsphere or microparticle according to claim 17 , wherein the formulation comprises an amount of psychoactive drug ranging from about 10% to about 40% by weight.
23. The formulation of claim 1 , wherein said tyrosine-derived polyarylate is comprised of a mixture of p(DTE-succinate) and p(DT-succinate) monomers.
24. The formulation of claim 1 , wherein said formulation is prepared as a solvent-cast film or a solvent-free film.
25. The formulation of claim 9 , wherein said said tyrosine-derived polyarylate is comprised of a mixture of p(DTE-succinate) and p(DT-succinate) monomers.